Why BGPT?
logo

Build Meta-analyses From Linked Results

Pull exact reported results from versioned records, each one traced to its paper.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start meta-analysis


     Quick Analysis Plan



    The supplied evidence records do not contain any data on gut ImP as a biomarker of atherosclerosis across cohorts; the available records cover unrelated entities (Drosophila IGF2BP/Imp, IMP-type carbapenemases, human bifunctional IMP synthase, Xanthomonas Imp). A defensible meta-analysis cannot be planned from these sources.


     Long Analysis Plan



    Requested Evidence Is Not Present

    No supplied source addresses intestinal Imai–Padilla-type, indole-3-propionate (ImP), or any gut-derived biomarker relative to atherosclerosis. The retrieved records instead cover: Drosophila maternal Imp/IGF2BP embryogenesis , IMP-family metallo-Ξ²-lactamase epidemiology , and in vitro IMP synthase kinetics . None report cohort-level effect sizes, sample sizes, or biomarker associations with atherosclerosis. What is missing: any human cohort with gut ImP measurements plus validated atherosclerosis outcomes (e.g., carotid IMT, plaque burden), enabling effect-size pooling with IΒ² heterogeneity assessment. I cannot plan or perform the requested meta-analysis without such data.

    Feedback:    

    Updated: September 11, 2026



     Top Data Sources ExportMCP



     Science Art


    Meta-analysis: Gut ImP biomarker atherosclerosis consistency across cohorts Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT